Bioprosthetic Tissue Calcification Mitigation via Stress-Induced Site Capping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bioprosthetic tissues used in implants, such as heart valves, face challenges with calcification and immune system reactions due to changes in the implant environment, which existing treatments do not adequately address, especially concerning stress-induced binding sites and long-term durability.
Innovation Solution
A method involving pre-stressing bioprosthetic tissue to expose potential calcification and immune binding sites, followed by applying a calcification mitigant, such as a capping agent or linking agent, to neutralize these sites, using agents like amines, amino acids, or long elastic molecules in various solutions, to reduce calcification and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioprosthetic tissue is implanted in the body, then it provides functional replacement for native tissue, but the connective tissue proteins become calcified following implantation causing stiffening or degradation
Solution Approach 1:
The patent applies preliminary action by exposing the bioprosthetic tissue to cyclic stress before implantation to simulate in vivo conditions, thereby exposing potential calcification binding sites in advance. This allows subsequent treatment with calcification mitigants to address these sites before the tissue is implanted, preventing calcification rather than treating it after it occurs.
Solution Approach 2:
The patent employs preliminary anti-action by applying calcification mitigants (such as capping agents or linking agents) to the stressed tissue before implantation. These agents bind to or neutralize the exposed binding sites that would otherwise attract calcium and initiate calcification, thereby preventing the harmful calcification process before it can occur in the implanted tissue.
2Stability of the object's composition
If chemical fixatives are used to preserve bioprosthetic tissue, then the tissue maintains structural integrity, but the tissue develops binding sites that attract calcium and phosphate leading to calcification
Solution Approach 1:
The patent applies preliminary action by subjecting the chemically fixed tissue to cyclic stress before implantation. This stress exposure occurs while the tissue is still in a controlled environment, allowing binding sites to be exposed in advance. Subsequent application of calcification mitigants can then address these sites before the tissue is implanted, preventing calcification while preserving the structural integrity provided by chemical fixation.
3Adaptability or versatility
If bioprosthetic tissue is stressed in the implant environment, then it adapts to functional demands, but new binding sites for calcification are created
Solution Approach 1:
The patent applies preliminary action by subjecting the bioprosthetic tissue to cyclic stress in advance, before implantation, to simulate the functional demands it will encounter in the body. This preliminary stress exposure causes binding sites to be exposed while the tissue is still accessible for treatment. Calcification mitigants are then applied to neutralize these sites before implantation, preventing calcification while maintaining the tissue's ability to adapt to functional demands.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces the propensity for calcification and immune reactions by permanently capping stress-induced binding sites, enhancing the durability and longevity of bioprosthetic implants by minimizing calcium and phosphate attraction, and improving tissue hydration and flexibility.
Implementation Method 1
The calcification mitigant may be a capping agent solution having at least one constituent that can bind to calcium, phosphate, or immunogenic factor binding sites
Implementation Method 2
The techniques used for chemical fixation of biological tissues typically involve the exposure of the biological tissue to one or more chemical fixatives (i.e., tanning agents) that form cross-linkages between the polypeptide chains within a given collagen molecule (i.e., intramolecular crosslinkages), or between adjacent collagen molecules (i.e., intermolecular crosslinkages)
Data Source
AI summary
A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant.